In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Researchers found that tirzepatide, a medication primarily used ... which may indicate a new direction for research possibilities. "For those living with obesity or diabetes, the field of weight loss ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

Using tirzepatide and menopause hormone therapy at the ... "This study underscores the urgent need for further research to ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Tirzepatide vs. Semaglutide for Obesity. 2025-07-03. DOI: 10.1056/NEJMdo008040 ... New research findings are summarized in a short video. Video Summary of. Original Article; May 11, 2025; ...